therosclerosis, the principal pathology underlying most cardiovascular disease, is characterized by a prominent infiltration of inflammatory cells into the vessel wall. [1] [2] [3] Whereas most research traditionally focuses on the inflammatory reaction in the intima of the vessel, the adventitia has not attracted much attention as an immune-active site. Recently, however, several experimental studies have demonstrated sparse distribution of leukocytes in the adventitia of healthy arteries 4 and massive accumulations of inflammatory cells around atherosclerotic vessels. 5 These conglomerates, observed preferentially around athero-prone areas of the vessel and termed vascular-associated lymphoid tissues, 6 contain T and B lymphocytes, dendritic cells, and lymphoid tissue inducer cells. Although the adventitia of nondiseased arteries contains a network of microvessels, termed vasa vasorum, vascular-associated lymphoid tissues are characterized by an extensive degree of neovascularization. Accordingly, Galkina et al 7 demonstrated that recruitment of lymphocytes to advanced atherosclerotic lesions is mainly mediated via this nonluminal site. In contrast, in early stages of atherosclerosis, leukocyte recruitment is facilitated through the luminal surface because the intimal and adventitial sites of inflammation are separated by several layers of smooth muscle cells (SMC) and intact elastic laminae. 8 Recently, Gräbner et al detailed the development and morphology of vascular-associated lymphoid tissues associated with advanced atherosclerosis in aged apolipoprotein E-deficient mice and coined the term aortic tertiary lymphoid organs (ATLO). 9 These structures harbor accumulations of B and T lymphocytes and dendritic cells, are a site of extensive neovascularization, and establish local connections to the intimal plaque by breaking down the elastic laminae. Furthermore, they suggested an orchestrating role for activation of SMC mediated by lymphotoxin ␤-receptor (LT␤R) in formation of these vascular-associated lymphoid tissues. 9 In this issue of Atherosclerosis Thrombosis and Vascular Biology, Lötzer et al 10 from the same group extend these studies and describe the transcriptional regulation of lymphorganogenic factors in this cell type in more detail. They isolated murine aortic SMC and stimulated those in vitro with recombinant tumor necrosis factor-␣ (TNF-␣), an agonistic antibody for LT␤R, or a combination of both. As expected, TNF-␣ promoted exclusively the classical NFB pathway, whereas ligation of LT␤R led to activation of both the classical and the alternative NFB pathway. Additionally, anti-LT␤R yielded a slower kinetic of activation, whereas TNF-␣ produced a rather rapid response. Their studies continue with a broad expression analysis revealing a unique transcriptional response in cultured SMC on combined stimulation with TNF-␣ and anti-LT␤R. 10 Interestingly, this combination resulted in a synergistically enhanced expression of several chemokines implicated in lymphorganogenesis (eg, CCL7, CCL9, CXCL13, CXCL16, CXCL13, and CCL19). Protein expression and functionality of SMC-derived chemokines were verified by immunoattraction and chemoattraction assays, respectively. Finally, using SMC from Ltbr Ϫ/Ϫ mice, Lötzer et al 10 could confirm the requirement of the synergistic activation, because these cells fail to produce the lymphoid tissue organizer cell-like expression pattern. Although the transformation of nonimmune cells to lymphoid tissue organizers is not novel, this study is the first to show such mechanisms in vascular SMC, suggesting a novel role in atherogenesis for this cell type.
Nonetheless, some questions remain unanswered and new issues are raised. The present work studies these pathways in murine cells; thus, these findings should be reproduced in human cells. Furthermore, to prove the concept of LT␤R signaling in SMC leading to lymphorganogenesis, future studies need to examine whether mice lacking LT␤R specifically on SMC-ideally using inducible gene deletion in an advanced disease model-do not develop ATLO.
This work also raises the question of which atheromaassociated cell type produces the ligands activating LT␤R, which is classically ligated by heteromers of LT␣ (TNF-SF1) and LT␤ (TNF-SF3). 11 When do these cells produce the lymphoid tissue organizer-inducing LT and TNF-␣? Which pathological triggers are needed? What are the consequences of ATLO formation? Does their formation eventually lead to plaque destabilization? Considering the extensive accumulation of T and B lymphocytes in ATLO, their role for the adaptive immune response in atherosclerosis requires further examination.
In the mouse, ATLO are found at very late stages of disease and almost exclusively at athero-prone areas of the abdominal aorta. Can we define the locations of ATLO in human atherosclerotic vessels? Why do we find so few ATLO in the mouse, and how many can we find in humans? Do they play a role in other vascular disease (eg, aneurysm formation and rupture)? In case that these lymphoid structures prove critical for the persistence and complication of atherosclerotic lesions or aneurysms, they may provide novel targets for the identification and treatment of critical lesions and patients. The concept developed by the group associated with Lötzer and Habenicht 10 suggests manipulation of SMCmediated lymphorganogenesis as a potential strategy. 
